A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
04/04/2022at 08:41

CEO of Novo Holdings: "We have executed the strategy we laid out when I joined"

Following a massive tailwind for Novo Nordisk and solid returns from the stock market, Novo Holdings can now boast of having over EUR 90bn in assets. Still, 2022 will be more difficult, says CEO Kasim Kutay.
Photo: Novo Holdings / PR
Finans
by benjamin werner christensen, translated by daniel pedersen

When Kasim Kutay took over as CEO of Novo Holdings in 2016, the company’s total assets were value under EUR 40bn. Now, five and a half years later, Novo Holding’s assets have reached a value of over EU90bn.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Kasim Kutay, CEO of Novo Holdings | Photo: Novo Holdings / PR

    Novo Holdings eyes opportunities as biotech bubble bursts

    For subscribers

  • Photo: Novo Holdings / PR

    Novo Holdings beats record as value of assets exceeds EUR 90bn

    For subscribers

  • Photo: Novo Holdings / PR

    Novo Holdings participates in series B round at Belgian cancer firm

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Foto: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Foto: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Foto: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Naveed Siddiqi, board director of Amolyt and senior partner at Novo Holdings, says Amolyt "is a great example of a high quality, late stage private European company." | Foto: Novo Ventures / PR
Pharma & biotech

Novo Holdings invests in biotech company for third time

A number of well-known life science actors have again invested in Amolyt Pharma, and Novo Holdings becomes a main shareholder.

For subscribers

Foto: Novo Holdings / PR
Pharma & biotech

Novo Holdings invests in newly merged blood disease company

US-based Disc Medicine merges with another hematological firm, and the new combined company raises USD 53.3m from a consortium of investors.

For subscribers

Benny Sørensen, CEO of Hemab Therapeutics | Foto: Hemab / PR
Pharma & biotech

Hemab doses first patient with candidate for rare blood disease

The biotech company, which uses technology from Novo Nordisk and Genmab, is expecting the first data from an early-stage study to arrive in H2 2023.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Principal Laboratory Technologist

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Clinical Operational Associate

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Head of Regulatory Affairs Danmark

See all jobs

Jobs

  • Principal Laboratory Technologist

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Lead Data Architect

  • Clinical Operational Associate

  • Commercial Director

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Head of Regulatory Affairs Danmark

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge